ANDA 213466, held by Aurobindo Pharma. Fexofenadine Hydrochloride.
As of Nov 22, 2026, ANDA 213466 (Fexofenadine Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on May 23, 2023, with 1 approved supplement and 0 published complete response letters.
Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 23, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fexofenadine Hydrochloride30MG/5ML · suspension;oral | Fexofenadine Hydrochloride | OTC |
| Aug 31, 2026 | Supplement 1Manufacturing | Approved | None posted |
| May 23, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters